Skip to main content
. 2015 Jan 30;6(8):5720–5734. doi: 10.18632/oncotarget.3122

Table 3. Relative Resistance indexes.

The IC50 fold increase obtained with mutant BaF-N/A cells is reported (wild-type N/A [WT] = 1), calculated from data in Table 2.

ASP3026 AP26113 alectinib crizotinib ceritinib PF-06463922
Ba/F3 parental 41 179 116 59 77 2508
WT 1 1 1 1 1 1
G1128S 15 0.7 2.1 2.8 5.0 10
C1156F 19 21 39 1.6 11 155
I1171N 7.4 5.2 28 5.0 9.1 9.5
I1171T 6.4 7.5 19 2.3 3.99 146
F1174I 2.6 0.9 0.8 1.0 0.6 1.9
N1178H 2.4 2.5 1.2 0.9 2.1 2.4
E1210K 11 15 31 1.97 9.1 57
C1156F/D1203N 40 10 4.0 11 12 54
RR legend
< 2 Sensitive
2–4 Slightly resistant
4–10 Fairly resistant
> 10 Highly resistant